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Types of vancomycin resistance in Staphylococcus aureus
There are two essential types of reduced vancomycin susceptibility in S. aureus: (1) that conferred by cell wall thickening resulting in a reduced susceptibility to vancomycin were associated with decreased pathogenicity and this correlated with decreased agr functional status 12 .
Testing for VISA and hVISA
Testing can be done using a number of methods, as summarised in Tables 1 and 2 . Are VISA/hVISA strains less susceptible to daptomycin?
Daptomycin is a large molecular weight compound with a site of action in the cell wall, like vancomycin, and it has been hypothesised that VISA/hVISA strains might be less susceptible to daptomycin.
A patient treated unsuccessfully with vancomycin but never treated with daptomycin, has a series of MRSA isolates from blood demonstrating increasing resistance to vancomycin and also daptomycin 16 .
Sakoulas et al. found MRSA strains that were heterogeneously resistant to vancomycin were also heterogeneously resistant to daptomycin 17 . Another group found MRSA MICs to daptomycin and vancomycin were strongly correlated (P > 0001, c 2 test) 18 .
Conclusions
If there is clinical failure of glycopeptide treatment of MRSA infection, especially bacteraemia, generally daptomycin or linezolid will be selected before screening or definitive testing for VISA/hVISA can be performed. In the case of MRSA bacteraemia, especially if endocarditis or other deep focus is present, the MIC should be determined, either by Etest (not modified Etest which is a screen for hVISA) or broth microdilution.
Fortunately most MRSA infections do not involve bacteraemia.
Vancomycin is cheap, generally well tolerated, has defined therapeutic drug monitoring strategies, and works well for the parenteral treatment of most MRSA infections.
Future directions
The clinical significance of hVISA needs to be defined. A cheap reliable test that predicts clinical failure with vancomycin is needed.
The role of daptomycin, linezolid and the new anti-MRSA cephalosporin ceftaroline in serious MRSA infections needs to be clarified.
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